Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 36, Issue 3, Pages 483-488Publisher
SPRINGER
DOI: 10.1007/s10557-021-07155-5
Keywords
Covid-19; SARS-CoV-2; Hypertension; Renin-angiotensin-aldosterone inhibitors; Drug safety; Calcium channel blockers
Funding
- French National Research Agency (ANR) under Investissements d'Avenir programs [ANR-10-IAHU-01]
- ANR PractikPharma grant [ANR-15-CE23-0028]
Ask authors/readers for more resources
Among Covid-19 patients with hypertension, there is a lower mortality rate among those using calcium channel blockers and beta-blockers, while there is no significant association between the use of renin-angiotensin-aldosterone system inhibitors and in-hospital death risk.
Purpose The role of angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACEi), or other antihypertensive agents in the case of Covid-19 remains controversial. We aimed to investigate the association between antihypertensive agent exposure and in-hospital mortality in patients with Covid-19. Methods We performed a retrospective multicenter cohort study on patients hospitalized between February 1 and May 15, 2020. All patients had been followed up for at least 30 days. Results Of the 8078 hospitalized patients for Covid-19, 3686 (45.6%) had hypertension and were included in the study. In this population, the median age was 75.4 (IQR, 21.5) years and 57.1% were male. Overall in-hospital 30-day mortality was 23.1%. The main antihypertensive pharmacological classes used were calcium channel blockers (CCB) (n=1624, 44.1%), beta-blockers (n=1389, 37.7%), ARB (n=1154, 31.3%), and ACEi (n=998, 27.1%). The risk of mortality was lower in CCB (aOR, 0.83 [0.70-0.99]) and beta-blockers (aOR, 0.80 [0.67-0.95]) users and non-significant in ARB (aOR, 0.88 [0.72-1.06]) and ACEi (aOR, 0.83 [0.68-1.02]) users, compared to non-users. These results remain consistent for patients receiving CCB, beta-blocker, or ARB as monotherapies. Conclusion This large multicenter retrospective of Covid-19 patients with hypertension found a reduced mortality among CCB and beta-blockers users, suggesting a putative protective effect. Our findings did not show any association between the use of renin-angiotensin-aldosterone system inhibitors and the risk of in-hospital death. Although they need to be confirmed in further studies, these results support the continuation of antihypertensive agents in patients with Covid-19, in line with the current guidelines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available